Guest Editor(s)
-
- Dr. Lombardi Giuseppe
- Department of Experimental and Clinical Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.
Website | E-mail
-
- Dr. Bellu Luisa
- Radiotherapy Department, Radiotherapist at Veneto Institute of Oncology-IRCCS, Padua, Italy.
E-mail
-
- Dr. Ius Tamara
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia Univeristy Hospital, Udine, Italy.
E-mail
-
- Dr. Villani Veronica
- Neurology Department, Neurologists at Regina Elena Hospital, Rome, Italy.
E-mail
-
- Dr. Caccese Mario
- Oncology Department, Veneto Institute of Oncology-IRCCS, Padua, Italy.
E-mail
Special Issue Introduction
Primary tumors are a heterogenous group of neoplasms originating from brain. Since 2016 we have had the new WHO classification incorporating new molecular characteristics, in particular IDH mutational status and 1p19q codeletion. Glioblastoma represents the most frequent primary brain tumor in adults and numerous studies were performed analyzing new treatments, such as regorafenib showing interesting results. Moreover, we have new approaches for radiotherapy and neurosurgery. New approaches for magnetic resonance imaging and positron emission tomography are integrated into diagnostic and follow up steps. Low grade gliomas and other primary and secondary brain tumors such as meningiomas or lung or melanoma metastases showed interesting responses to new treatment, in particular to combination of radiotherapy, immunotherapy and targeted therapy.This special issue will cover all aspects of primary and secondary brain tumors including current treatment options, radiation therapy, surgery, immunotherapy, imaging and molecular characteristics. Reviews will also be gratefully accepted.
Keywords
Brain tumors, immunotherapy, brain metastases, glioblastoma
Submission Deadline
31 Jan 2021